For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Over two thirds of patients with hidradenitis suppurativa experience fewer flares, new lesions, and improved quality of life ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

About The Study: In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated with increased risk of psychiatric adverse ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.